DeFloria’s advances cannabis-based autism drug through early trial

If successful in later trials, it could become one of the first FDA-approved botanical drugs derived from hemp for autism spectrum disorder.

DeFloria announced Thursday that its experimental cannabis-based drug for autism spectrum disorder showed positive early results, with patients tolerating the treatment well across multiple dose levels.